Aclarion Implements 1-for-370 Reverse Stock Split to Maintain Nasdaq Listing

Healthcare technology company Aclarion (Nasdaq: ACON) has announced a 1-for-370 reverse stock split of its common stock, effective January 29, 2025, in a strategic move to maintain its Nasdaq listing status. The decision comes as the company aims to meet Nasdaq's continued listing requirement of maintaining a minimum bid price of $1.00 per share.

The reverse split, which received stockholder approval on December 31, 2024, will dramatically reduce Aclarion's outstanding shares from approximately 185 million to 500,000. Under the terms of the split, every 370 existing shares will be automatically combined into one share, with fractional shares being rounded up to the nearest whole share.

This corporate action carries significant implications for investors and the company's market presence. The restructuring will affect all of Aclarion's securities, including outstanding warrants, stock options, and restricted stock units, with proportional adjustments to their conversion and exercise prices. Existing stockholders with shares in brokerage accounts will see their holdings automatically adjusted, while those holding physical certificates will receive specific exchange instructions from the company's transfer agent.

The move represents a critical juncture for Aclarion, which specializes in chronic low back pain diagnosis technology. While reverse splits are often viewed as technical maneuvers, maintaining a Nasdaq listing is crucial for the company's visibility, access to capital markets, and ability to advance its healthcare technology initiatives. The success of this strategy will largely depend on the market's response and the company's ability to maintain its post-split share price above the crucial $1.00 threshold.